LBC_FNAs (SurePath) |
Thyroid |
Papillary carcinoma (n=8) |
TG+, TTF1+, CK19+, galectin 3+, CD56–, HBME1+, PTH– |
Papillary thyroid carcinoma |
Suspicious for papillary carcinoma (n=2) |
TG+, TTF1+, CK19+, galectin 3+, CD56–, HBME1+, PTH– |
Papillary thyroid carcinoma |
Nodular hyperplasia (n=12) |
TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– |
Nodular hyperplasia |
Atypia (n=4) |
TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– |
Nodular hyperplasia |
Atypia (n=1) |
TG–, TTF1–, CK19+, galectin 3–, CD56–, HBME1–, PTH+ |
Parathyroid lesion |
Benign Hurthle cell proliferation (n=2) |
TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– |
Benign Hurthle cell lesion |
Chronic lymphocytic thyroiditis (n=2) |
N/A due to scanty cellularity |
N/A |
Lymph node |
Lymphoid malignancy (n=2) |
CD45–, CD20–, CD3–, TdT+, PAX5+, CD56– |
B-lymphoblastic lymphoma |
|
CD45+, CD20+, CD3–, TdT–, PAX5+, CD56– |
Large B-cell lymphoma |
LBC_serous effusions (SurePath) |
Ascitic fluid |
Lymphoid malignancy (n=1) |
CD45+, CD20–, CD3–, TdT+, PAX5+, CD56– |
B-lymphoblastic lymphoma |
Adenocarcinoma (n=1) |
CK7+, CK19+, calretinin–, D2-40, WT1+, CD56–, TTF1– |
Ovarian serous carcinoma |
Pleural effusion |
Adenocarcinoma (n=1) |
CK7+, CK19+, calretinin–, D2-40–, HBME1–, WT1–, TTF1+ |
Adenocarcinoma of lung primary |
Favor malignant mesothelioma (n=1) |
CK7+, CK19+, calretinin+, D2-40+, HBME1+, WT1+, TTF1– |
Malignant mesothelioma |
Negative for malignancy (n=1) |
N/A |
N/A |